ANI Pharmaceuticals to Present at Upcoming December Investor Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ANI Pharmaceuticals (ANIP) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 1, 2026. President and CEO Nikhil Lalwani and other executives will join the chat at 12:30 p.m. ET. Live and archived webcasts will be available in the Events and Presentations area of the company’s Investors section.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in a fireside chat at the following upcoming investor conference:
| Event | Piper Sandler Healthcare Conference |
| Date | Tuesday, December 1, 2026 |
| Time | 12:30 p.m. ET |
| Webcast | Click here |
The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com
Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com
SOURCE: ANI Pharmaceuticals, Inc.